The Last Mile Nobody Talks About: What Really Happens To Unused Clinical Trial Supplies

By Laura Hay, Senior Director of Global Program Management at Trax Group | 2025 Winner, everywoman Customer/Passenger (Leader) Award

When most people think about clinical trials, they imagine scientists in white coats, life-changing discoveries, and medicines making their way to patients. Very few picture a warehouse full of investigational product waiting for someone to decide what happens next.

And that's probably fair. It's hardly the glamorous side of pharmaceutical research.

But if you've ever worked in clinical supply, you'll know that the end of a clinical trial doesn't actually feel like the end of anything. The study team is celebrating. The data managers are already talking about database lock. Senior leaders are asking about the next program. Somewhere, there's probably cake in the office.

Meanwhile, you're looking at inventory reports from multiple countries wondering why one site says it has six kits left while the system insists there should be nine.

Welcome to the part of clinical research nobody writes about. Ironically, it's often the point where you discover just how good your supply chain really is.

Success Doesn't End With The Last Patient

There's a lot of attention given to getting investigational product to the right patient, at the right site, at the right time. As there should be. Patients are relying on us, and delays simply aren't an option.

But once the final patient has completed treatment, the challenge changes.

Now every vial, every tablet, every syringe, and every kit has to be accounted for. What remains? What was dispensed? What expired? What can be returned? What must be destroyed? Can every movement be evidenced if an auditor asks six months from now?

Unlike many commercial supply chains, "close enough" isn't a phrase that exists in clinical research. Every single unit matters.

We Spend Years Planning Distribution, Then We Forget About The Journey Home

Clinical supply teams are exceptional at getting products where they need to be. Manufacturing schedules, cold chain logistics, depot strategies, import documentation, and site activation all require incredibly sophisticated planning.

Then the study ends. Suddenly, bringing product back turns out to be significantly more complicated than sending it out in the first place.

Some countries allow returns. Others insist on local destruction. Some require independent witnesses during destruction. Others have customs requirements that seem determined to test everyone's patience. And just when you think you've seen every possible scenario, another country introduces a process you've never encountered before.

If clinical supply has taught me anything, it's to never assume every country sees things the same way. Because they don't.

Nobody Gets Applauded For Perfect Reconciliation

Let's be honest. Nobody stands on stage at an industry conference to collect an award for "Outstanding Inventory Reconciliation."

Perhaps they should, because this work matters.

Behind every returned shipment is a chain of accountability. Sponsors need confidence that every investigational product has been handled appropriately. Regulators need confidence that trial records are complete. Clinical teams need confidence that patient treatment records are accurate. Most importantly, patients deserve confidence that every aspect of the study has been managed to the same standard from beginning to end.

Good reconciliation rarely attracts attention. Poor reconciliation certainly does.

The Sustainability Conversation Is Getting Louder

One topic I believe we'll hear much more about over the next few years is waste.

The pharmaceutical industry is making significant commitments around sustainability, yet clinical trials inevitably generate unused investigational product. That's not because anyone has done anything wrong. In fact, it's often the opposite.

Clinical supply professionals are naturally cautious. Nobody wants to be responsible for a patient not receiving treatment because the forecast was too optimistic. So, we build safety stock. Then a little more. Then just enough contingency stock to help everyone sleep at night.

Sometimes that's exactly the right decision. But it's also worth asking ourselves an uncomfortable question: Are we protecting patients, or are we sometimes protecting ourselves from the possibility of getting the forecast wrong? They're not always the same thing.

Forecasting Isn't Something You Do Once

One of the biggest shifts I've seen over recent years is how organizations think about forecasting.

Historically, forecasts were often developed at the beginning of a study and adjusted only when something significant happened. Today's trials move much faster. Recruitment changes. Sites activate earlier than expected. Protocols evolve. Countries perform differently. The original forecast quickly becomes exactly that — original.

The organizations making the biggest strides are treating forecasting as a living process rather than a document. Using real-time data to make small adjustments throughout a study is far more effective than making one enormous correction six months later.

It's not about predicting the future perfectly. It's about responding intelligently when reality changes.

Visibility Is Brilliant, Unless Nobody Does Anything With It

Every technology provider promises visibility — real-time dashboards, live inventory, predictive analytics, and control towers. Don't get me wrong, these tools are incredibly valuable. But visibility isn't the same as control.

Knowing there's excess stock sitting in three countries doesn't solve anything if nobody has the authority to move it. Seeing a potential shortage doesn't help if teams spend two weeks deciding whose responsibility it is.

Technology should help people make better decisions. It shouldn't become another dashboard people admire before opening the next spreadsheet. And yes, somehow there is always another spreadsheet.

Great Supply Chains Are Built On Relationships

One thing I've learned throughout my career is that supply chains don't succeed because every process works perfectly. They succeed because people work well together when things don't.

Clinical supply is one of the most collaborative environments I've ever worked in. Sponsors, depots, manufacturers, logistics providers, clinical sites, home healthcare partners, and regulatory teams all play critical roles. No single organization controls the whole process, which means trust becomes just as important as technology.

The strongest programs aren't the ones where nothing ever goes wrong. They're the ones where everyone is honest about what's happening and focuses on solving the problem rather than protecting their corner. That kind of collaboration can't be written into a standard operating procedure. It's built over time.

Looking Beyond The Finish Line

People often ask me what makes a great clinical supply chain.

It isn't perfection.

Something will always change. A flight will be canceled. A protocol will be amended. Recruitment will surprise you. Someone will discover inventory that everyone thought had already been reconciled. That's simply the nature of global operations.

The organizations that stand out aren't the ones that avoid these moments. They're the ones that respond quickly, communicate openly, and never lose sight of why they're doing it. Because behind every shipment, every return, every reconciliation, and every inventory report is a patient.

Clinical supply has never really been about moving products. It's about making sure patients receive the treatments they need, exactly when they need them, while protecting the integrity of the science that could improve countless more lives in the future.

That's why I believe the last mile deserves far more attention than it gets. Not because it's the end of the supply chain, but because it's where operational excellence quietly proves itself.

About The Author:

Laura Hay is a global supply chain leader specializing in program management, customer success, and account strategy. She has a proven track record of leading cross-functional teams to deliver complex, high-impact initiatives on time and within budget. Laura is known for building strong stakeholder relationships, driving operational excellence, and managing multimillion-dollar programs. She is passionate about connecting people, processes, and technology to build scalable, resilient supply chain solutions that deliver measurable business impact.